Treatment of subcutaneous sarcoidosis with hydroxychloroquine: report of 2 cases.
Although the therapeutic benefit of oral antimalarials in various types of sarcoidosis is well described, their reported use specifically in subcutaneous sarcoidosis (Darier-Roussy type sarcoidosis) is limited. We describe the cases of two patients with subcutaneous sarcoidosis treated with hydroxychloroquine, suggesting that it may represent an alternative first-line treatment for patients in whom steroid-sparing therapy is desired.
Memorial Sloan-Kettering Cancer Center.
Michael
M
Marchetti
Mary Grace
MG
Baker
Mary-Margaret B
MM
Noland
D000305:Adrenal Cortex Hormones; D001706:Biopsy; D000075202:Contraindications; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012507:Sarcoidosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D017565:Sarcoidosis, Pulmonary / Q000150:complications; D040521:Subcutaneous Tissue / Q000473:pathology
D000305:Adrenal Cortex Hormones; D006886:Hydroxychloroquine; D011241:Prednisone